Background The multicenter double-blind, randomized Bergamo Nephrologic Diabetes
Complications Trial (BENEDICT) was designed to assess whether angiotensin-converting–…

Background Autosomal dominant polycystic kidney disease slowly progresses to end-stage
renal disease and has no effective therapy. A pilot study suggested that the somatostatin …

The outcome of steroid-dependent or frequently relapsing nephrotic syndrome of minimal
change disease (MCD), mesangial proliferative GN (MesGN), or FSGS may be poor and with …

Activation of mammalian target of rapamycin (mTOR) pathways may contribute to
uncontrolled cell proliferation and secondary cyst growth in patients with autosomal dominant …

To assess whether angiotensin-converting enzyme inhibitors and third-generation
dihydropyridine calcium channel blockers ameliorate diabetic complications, we compared …

Background Effective home treatment algorithms implemented based on a pathophysiologic
and pharmacologic rationale to accelerate recovery and prevent hospitalisation of patients …

Micro-or macroalbuminuria is associated with increased cardiovascular risk factors among
patients with type 2 diabetes, but whether albuminuria within the normal range predicts long-…

Objectives To address whether nondihydropyridine calcium-channel blocker added-on
angiotensin-converting-enzyme inhibitor therapy ameliorates albuminuria and cardiovascular …

Unrestrained activation of the complement system till the terminal products, C5a and C5b-9,
plays a pathogenetic role in acute and chronic inflammatory diseases. In endothelial cells, …

Background Autosomal dominant polycystic kidney disease (ADPKD) is the most frequent
genetically determined renal disease. In affected patients, renal function may progressively …